Standout Papers
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma (2011)
- Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases (2011)
Immediate Impact
1 by Nobel laureates 5 from Science/Nature 56 standout
Citing Papers
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
2022 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Works of David H. Henry being referenced
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
2012
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
2011 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| David H. Henry | 1852 | 3344 | 725 | 955 | 122 | 5.6k | |
| Saroj Vadhan‐Raj | 3177 | 3505 | 972 | 447 | 169 | 7.6k | |
| Pere Gascón | 1251 | 2920 | 454 | 105 | 163 | 5.6k | |
| Giuseppe Avvisati | 5056 | 1558 | 946 | 632 | 199 | 7.5k | |
| Linda J. Burns | 3678 | 3157 | 985 | 135 | 196 | 7.5k | |
| Joachim Kienast | 3386 | 1153 | 867 | 83 | 96 | 7.2k | |
| James H. Feusner | 2445 | 1243 | 301 | 148 | 148 | 5.9k | |
| Peter F. Coccia | 1732 | 1504 | 952 | 66 | 107 | 5.6k | |
| Judith Marsh | 6411 | 1834 | 1960 | 86 | 209 | 8.8k | |
| Marcella M. Johnson | 204 | 2858 | 192 | 420 | 74 | 5.3k | |
| F R Appelbaum | 5936 | 2874 | 1200 | 60 | 99 | 8.4k |
All Works
Login with ORCID to disown or claim papers
Loading papers...